ReviewRadiology. Imaging cancer2020
MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive Review.
Review in Radiology. Imaging cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Pooled it
- Intra-ablational and peri-ablational radiomics based on post-RFA gadoxetic acid disodium-enhanced MRI for predicting short-term prognosis in hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Histopathological outcomes of CT-guided high-dose-rate interstitial brachytherapy for HCC and predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm v2024.European radiology · 2026Article
- Personalized dosimetry enhances hepatocellular carcinoma response in Yttrium-90 resin microsphere radioembolization.European radiology · 2026Article
- Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024.Journal of magnetic resonance imaging : JMRI · 2026Article
- MRI after Interventional Therapy of Hepatocellular Carcinoma: Typical Changes over Time.RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin · 2026Review
- Role of MRI in Imaging Assessment of Radiation-Based Treatment of Hepatocellular Carcinoma.Cancers · 2026Review
- LI-RADS TRA V2024: innovations in imaging assessment of hepatocellular carcinoma response to locoregional therapies.Abdominal radiology (New York) · 2026Review
- Longitudinal MRI changes after focal therapy for prostate cancer: cryotherapy vs. microwave tissue coagulation.Japanese journal of radiology · 2025Article
- Hepatocellular carcinoma treatment response: Imaging findings and criteria.World journal of radiology · 2025Review
- Can ADC changes help mRECIST or LI-RADS treatment response algorithm better diagnose pathological response of HCC after preoperative radiotherapy? Secondary analysis of a prospective phase 2 trial.Insights into imaging · 2025Article
- Prognostic value of preoperative fibrinogen, neutrophil-to-lymphocyte ratio, serum alpha-fetoprotein, and prealbumin for patients with primary liver cancer undergoing transarterial chemoembolization.World journal of gastrointestinal oncology · 2025Article
- Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.Journal of gastroenterology · 2025Article
- LI-RADS radiation-based treatment response algorithm for HCC: what to know and how to use it.Abdominal radiology (New York) · 2025Review
- LI-RADS CT/MRI Treatment Response Assessment Update in 2024.Journal of the Korean Society of Radiology · 2025Review
- CT/MRI technical pitfalls for diagnosis and treatment response assessment using LI-RADS and how to optimize.Abdominal radiology (New York) · 2025Review
- Review
- Current Treatment Methods in Hepatocellular Carcinoma.Cancers · 2024Review
- CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.Radiology · 2024Review
- Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.Radiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nearly 80% of cirrhotic patients diagnosed with hepatocellular carcinoma (HCC) are not eligible for surgical resection and instead undergo local-regional treatment. After therapy for HCC, patients undergo imaging surveillance to assess treatment efficacy and identify potential sites of progressive tumor elsewhere within the liver. Accurate interpretation of posttreatment imaging is essential for guiding further management decisions, and radiologists must understand expected treatment-specific imaging findings for each of the local-regional therapies. Of interest, expected imaging findings seen after radiation-based therapies (transarterial radioembolization and stereotactic body radiation therapy) are different than those seen after thermal ablation and transarterial chemoembolization. Given differences in expected posttreatment imaging findings, the current radiologic treatment response assessment algorithms used for HCC (modified Response Evaluation Criteria in Solid Tumors classification, European Association for the Study of Liver Diseases criteria, and Liver Imaging and Reporting Data System Treatment Response Algorithm) must be applied cautiously for radiation-based therapies in which persistent arterial phase hyperenhancement in the early posttreatment period is common and expected. This article will review the concept of tumor response assessment for HCC, the forms of local-regional therapy for HCC, and the expected posttreatment findings for each form of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.